Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Oncotelic Therapeutics Inc (OTLC)

Oncotelic Therapeutics Inc (OTLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer Globe Newswire - Tue Jul 12, 2022

AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...

OTLC : 0.0223 (-2.19%)
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention Globe Newswire - Wed Jun 15, 2022

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...

OTLC : 0.0223 (-2.19%)
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) Globe Newswire - Wed May 25, 2022

AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of...

OTLC : 0.0223 (-2.19%)
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE Globe Newswire - Mon May 23, 2022

AGOURA HILLS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced...

OTLC : 0.0223 (-2.19%)
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention Globe Newswire - Wed May 18, 2022

AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...

OTLC : 0.0223 (-2.19%)
ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE Globe Newswire - Mon Apr 18, 2022

AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced...

OTLC : 0.0223 (-2.19%)
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited Globe Newswire - Thu Apr 7, 2022

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following...

OTLC : 0.0223 (-2.19%)
Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022 Globe Newswire - Thu Mar 10, 2022

●OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β●OT-101 has completed over six clinical trials against solid tumors with good efficacy●OT-101 is...

OTLC : 0.0223 (-2.19%)
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit Globe Newswire - Thu Mar 3, 2022

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are...

OTLC : 0.0223 (-2.19%)
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference Globe Newswire - Thu Feb 24, 2022

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently...

OTLC : 0.0223 (-2.19%)

Barchart Exclusives

Will OJ Continue to Make New Highs? Barchart - Thu Sep 26, 2:00PM CDT
Frozen concentrated orange juice is one of the five soft commodities. FCOJ has the distinction as the most illiquid, meaning it suffers from the lowest volume and open interest. Like many soft commodities, FCOJ has been on a bullish run, but unlike the others, it reached a new record high in September 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot